Hot Natural Products & Bioactive Compounds

BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.

Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.

Hot Products from BioCrick

Showing 545 - 552 of 9359 hot products

BioCrick hot natural products and bioactive compounds
Catalog No. Product Name
BCC2509 Ispinesib (SB-715992)
High affinity allosteric kinesin spindle protein (KSP) inhibitor (Ki app = 1.7 nM). Exhibits >10,000-fold selectivity for KSP over a range of other mitotic kinesins. Inhibits proliferation and induces apoptosis of prostate and breast cancer cells in vitro. Induces tumor regression of breast cancer cell xenografts in mice.
BCC2512 Zonisamide
Antiepileptic that possesses a broad spectrum anticonvulsant and mechanistic profile. Blocks voltage-sensitive Na+ and T-type Ca2+ channels, stimulates BKCa channels, modulates GABA, glutamate and monoamine neurotransmission, inhibits lipid peroxidation and scavenges hydroxyl and nitric oxide free radicals. Displays neuroprotective and antiParkinsonian activity.
BCC2513 Venlafaxine Hydrochloride
Dual serotonin/noradrenalin re-uptake inhibitor that displays ~ 30-fold higher affinity for SERT than NET (Ki values are 82 and 2480 nM respectively). Antidepressant; increases swimming and climbing behavior in the forced-swim test in rats.
BCC2514 Tranilast
Antiallergic via inhibition of chemical mediator release from mast cells. Shown to be an effective inhibitor of angiogenesis. Demonstrated to antagonize the effects of angiotensin II on human arteries, possibly by an interaction at the level of the AT<sub>1</sub> receptor. Inhibits TRPV2-mediated responses; binds to A<span class='symbol'>&#946;</span>40 monomers and increases A<span class='symbol'>&#946;</span>40 fibrillation.
BCC2515 Zileuton
Orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB<sub>4</sub> synthesis (IC<sub>50</sub> values are 0.56, 2.3 and 2.6 <span class='symbol'>&#956;</span>M in dog, rat and human blood respectively). Inhibits antigen-induced contraction of tracheal strips <em>in vitro</em> (IC<sub>50</sub> = 6 <span class='symbol'>&#956;</span>M) and exhibits antiasthmatic activity <em>in vivo</em>. Also weakly inhibits CYP1A2 (K<sub>i</sub> = 66 - 98 <span class='symbol'>&#956;</span>M).
BCC2518 Fludarabine
Purine analog that inhibits DNA synthesis. Exhibits antiproliferative activity (IC<sub>50</sub> = 1.54 <span class='symbol'>&#956;</span>M in RPMI cells) and triggers apoptosis through increasing Bax and decreasing Bid, XIAP and survivin expression. Inhibits cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in lymphocytes. Also displays anticancer activity against hematological malignancies <em>in vivo</em>.
BCC2520 AEE788 (NVP-AEE788)
Potent EGFR and VEGFR inhibitor (IC50 values are 2, 6, 59, 77, 160 and 330 nM for EGFR, ErbB2, VEGFR-1, VEGFR-2, ErbB4 and VEGFR-3 respectively). Also inhibits c-Abl, c-Fms and c-Src (IC50 values are 52, 60 and 61 nM respectively). Inhibits proliferation of EGFR and ErbB2 overexpressing cancer cell lines in vitro. Inhibits tumor xenograft growth and VEGF-induced angiogenesis in mice. Orally active.
BCC2522 Ponatinib (AP24534)
Potent multi-kinase and pan-Bcr-Abl inhibitor. Displays potent activity against cell lines expressing native Bcr-Abl or Bcr-Abl<sup>T3151</sup> (IC<sub>50</sub> values are 0.37 and 2.0 nM respectively); also inhibits other Abl kinase domain mutants at nanomolar potencies. Exhibits inhibitory activity against PDGFR<span class='symbol'>&#945;</span>, c-Src and c-Kit (IC<sub>50</sub> values are 1.1, 5.4 and 12.5 nM respectively); potently inhibits FGFR and VEGFR family kinases. Orally active.